Drugmaker Johnson & Johnson has halted manufacturing of its single-dose COVID-19 vaccine, in response to a New York Instances report.

The pharmaceutical firm final 12 months quietly shut down manufacturing at a plant in Leiden, Netherlands, which was the one facility the place usable doses of the vaccine had been manufactured, catching a few of its prospects off guard, together with creating nations that want the single-dose J&J drug over two-dose options, the report states. 

Johnson & Johnson has as a substitute been utilizing the plant to work on an experimental and probably extra worthwhile drug that might defend in opposition to an unrelated respiratory virus, in response to the report. 

The plant is predicted to renew manufacturing of the COVID-19 vaccine, however it’s unclear when. 

J&J didn’t touch upon the plant closure studies, however mentioned in an announcement to CBS Information “we at the moment have hundreds of thousands of doses of our COVID-19 vaccine in stock” and “we proceed to satisfy our contractual obligations … [to] the African Union.” 

Vaccine of selection for poorer international locations

The J&J vaccine, known as the Janssen COVID-19 vaccine, made by Janssen Biotech, a subsidiary of Johnson & Johnson, is the vaccine of selection for poorer international locations which can be relying on the drugmaker to assist them struggle the pandemic. 


COVID deaths nonetheless rising as circumstances drop

01:48

Wealthier nations just like the U.S. have favored photographs from Moderna and Pfizer, as a result of the 2 look like simpler in opposition to COVID-19 variants like Omicron, and since the Janssen vaccine has, prior to now, been linked to uncommon however probably life-threatening blood clots. 

On condition that just one dose of the J&J vaccine is required, although, it is inexpensive than its double-dose counterparts and in addition simpler to ship, making it standard in lower-income international locations. 

By

Leave a Reply

Your email address will not be published.